Skip to main content
Log in

The malignant melanoma landscape

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

An Erratum to this article was published on 11 July 2014

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: US sales of therapies for malignant melanoma, by drug class (estimated).

Change history

  • 04 July 2014

    In the text of the article, cobimetinib was incorrectly described as a BRAF inhibitor, but is actually a MEK inhibitor. The online version of the article has been corrected accordingly.

References

  1. Decision Resources Group. Malignant Melanoma (Pharmacor; 2013–2014).

  2. Decision Resources Group. Immunotherapies (Pharmacor; 2014).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rachel M. Webster.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Webster, R., Mentzer, S. The malignant melanoma landscape. Nat Rev Drug Discov 13, 491–492 (2014). https://doi.org/10.1038/nrd4326

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4326

  • Springer Nature Limited

This article is cited by

Navigation